A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Simtuzumab (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms RAINIER
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 May 2017 Results (n=70) assessing relationship between progression determined by forced vital capacity (FVC) and quantitative HRCT, presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of a retrospective analysis of the control arm presented at the 113th International Conference of the American Thoracic Society
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top